JPWO2021029430A1 - - Google Patents

Info

Publication number
JPWO2021029430A1
JPWO2021029430A1 JP2021539312A JP2021539312A JPWO2021029430A1 JP WO2021029430 A1 JPWO2021029430 A1 JP WO2021029430A1 JP 2021539312 A JP2021539312 A JP 2021539312A JP 2021539312 A JP2021539312 A JP 2021539312A JP WO2021029430 A1 JPWO2021029430 A1 JP WO2021029430A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539312A
Other languages
Japanese (ja)
Other versions
JPWO2021029430A5 (https=
JP7148733B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021029430A1 publication Critical patent/JPWO2021029430A1/ja
Publication of JPWO2021029430A5 publication Critical patent/JPWO2021029430A5/ja
Priority to JP2022150733A priority Critical patent/JP7635187B2/ja
Application granted granted Critical
Publication of JP7148733B2 publication Critical patent/JP7148733B2/ja
Priority to JP2025020427A priority patent/JP2025072595A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021539312A 2019-08-13 2020-08-13 複素環化合物を含有する経口医薬組成物 Active JP7148733B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022150733A JP7635187B2 (ja) 2019-08-13 2022-09-21 複素環化合物を含有する経口医薬組成物
JP2025020427A JP2025072595A (ja) 2019-08-13 2025-02-12 複素環化合物を含有する経口医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2019/031895 WO2021029020A1 (ja) 2019-08-13 2019-08-13 経口医薬組成物
JPPCT/JP2019/031895 2019-08-13
PCT/JP2020/030777 WO2021029430A1 (ja) 2019-08-13 2020-08-13 複素環化合物を含有する経口医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022150733A Division JP7635187B2 (ja) 2019-08-13 2022-09-21 複素環化合物を含有する経口医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2021029430A1 true JPWO2021029430A1 (https=) 2021-02-18
JPWO2021029430A5 JPWO2021029430A5 (https=) 2022-06-22
JP7148733B2 JP7148733B2 (ja) 2022-10-05

Family

ID=74569440

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2021539751A Withdrawn JPWO2021029020A1 (https=) 2019-08-13 2019-08-13
JP2021539311A Active JP7110495B2 (ja) 2019-08-13 2020-08-13 経口医薬組成物
JP2021539312A Active JP7148733B2 (ja) 2019-08-13 2020-08-13 複素環化合物を含有する経口医薬組成物
JP2022112389A Pending JP2022132411A (ja) 2019-08-13 2022-07-13 経口医薬組成物
JP2022150733A Active JP7635187B2 (ja) 2019-08-13 2022-09-21 複素環化合物を含有する経口医薬組成物
JP2025020427A Pending JP2025072595A (ja) 2019-08-13 2025-02-12 複素環化合物を含有する経口医薬組成物
JP2025027501A Pending JP2025074104A (ja) 2019-08-13 2025-02-25 経口医薬組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021539751A Withdrawn JPWO2021029020A1 (https=) 2019-08-13 2019-08-13
JP2021539311A Active JP7110495B2 (ja) 2019-08-13 2020-08-13 経口医薬組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022112389A Pending JP2022132411A (ja) 2019-08-13 2022-07-13 経口医薬組成物
JP2022150733A Active JP7635187B2 (ja) 2019-08-13 2022-09-21 複素環化合物を含有する経口医薬組成物
JP2025020427A Pending JP2025072595A (ja) 2019-08-13 2025-02-12 複素環化合物を含有する経口医薬組成物
JP2025027501A Pending JP2025074104A (ja) 2019-08-13 2025-02-25 経口医薬組成物

Country Status (15)

Country Link
US (4) US20220273647A1 (https=)
EP (2) EP4015001A4 (https=)
JP (7) JPWO2021029020A1 (https=)
KR (2) KR20220046625A (https=)
CN (2) CN114222562A (https=)
AU (2) AU2020328351B2 (https=)
BR (2) BR112022002433A2 (https=)
CA (2) CA3150751A1 (https=)
IL (2) IL290469B2 (https=)
MX (3) MX2022001758A (https=)
MY (2) MY208261A (https=)
PH (2) PH12022550347A1 (https=)
TW (2) TWI870441B (https=)
WO (3) WO2021029020A1 (https=)
ZA (2) ZA202202319B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
CN118742293A (zh) * 2022-01-31 2024-10-01 住友精化株式会社 药物控释制剂用组合物和药物控释制剂
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤
AU2024247059A1 (en) * 2023-03-29 2025-10-30 Merck Sharp & Dohme (Uk) Limited Controlled release pde10a formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008115172A (ja) * 2006-10-13 2008-05-22 Otsuka Pharmaceut Co Ltd 医薬
JP2014510023A (ja) * 2011-04-05 2014-04-24 大塚製薬株式会社 ブレクスピプラゾール又はその塩及び第二薬剤を含有する中枢神経疾患を治療するための組合せ薬剤
JP2018177679A (ja) * 2017-04-11 2018-11-15 学校法人帝京大学 抗カンジダ活性組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (https=) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP2911670A1 (en) * 2012-10-25 2015-09-02 Otsuka Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
CN106667969A (zh) * 2017-02-23 2017-05-17 佛山市弘泰药物研发有限公司 一种依匹哌唑缓释胶囊及其制备方法
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008115172A (ja) * 2006-10-13 2008-05-22 Otsuka Pharmaceut Co Ltd 医薬
JP2014510023A (ja) * 2011-04-05 2014-04-24 大塚製薬株式会社 ブレクスピプラゾール又はその塩及び第二薬剤を含有する中枢神経疾患を治療するための組合せ薬剤
JP2018177679A (ja) * 2017-04-11 2018-11-15 学校法人帝京大学 抗カンジダ活性組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
川上亘作, 医薬品開発における結晶多形の制御と評価, JPN6020039026, 2011, pages 98 - 99, ISSN: 0004824496 *
川上亘作, 難水溶性薬物の経口製剤化技術最前線, JPN6020039025, 2016, pages 68 - 73, ISSN: 0004824495 *

Also Published As

Publication number Publication date
CN114222575A (zh) 2022-03-22
MX2022001758A (es) 2022-05-13
JPWO2021029020A1 (https=) 2021-02-18
PH12022550349B1 (en) 2024-03-06
BR112022002433A2 (pt) 2022-12-13
MY208261A (en) 2025-04-29
MY208267A (en) 2025-04-29
JPWO2021029429A1 (https=) 2021-02-18
AU2020327792A1 (en) 2022-03-24
TW202120090A (zh) 2021-06-01
CA3150751A1 (en) 2021-02-18
PH12022550347A1 (en) 2022-12-12
KR20220046625A (ko) 2022-04-14
AU2020328351A1 (en) 2022-03-24
JP2022180531A (ja) 2022-12-06
WO2021029430A1 (ja) 2021-02-18
EP4015002A4 (en) 2023-06-07
AU2020327792B2 (en) 2026-03-05
TWI870441B (zh) 2025-01-21
CA3150827A1 (en) 2021-02-18
IL290472A (en) 2022-04-01
IL290469B2 (en) 2025-08-01
TW202120091A (zh) 2021-06-01
IL290469B1 (en) 2025-04-01
CN114222562A (zh) 2022-03-22
WO2021029429A1 (ja) 2021-02-18
BR112022002436A2 (pt) 2022-12-13
TW202517267A (zh) 2025-05-01
MX2025006039A (es) 2025-07-01
EP4015001A4 (en) 2023-06-14
JP7148733B2 (ja) 2022-10-05
JP2025072595A (ja) 2025-05-09
TWI870442B (zh) 2025-01-21
MX2022001759A (es) 2022-05-13
JP2022132411A (ja) 2022-09-08
EP4015002A1 (en) 2022-06-22
JP2025074104A (ja) 2025-05-13
IL290469A (en) 2022-04-01
WO2021029020A1 (ja) 2021-02-18
ZA202202319B (en) 2024-06-26
TW202517266A (zh) 2025-05-01
US20250057835A1 (en) 2025-02-20
KR20220046624A (ko) 2022-04-14
EP4015001A1 (en) 2022-06-22
US20220273647A1 (en) 2022-09-01
US20250127776A1 (en) 2025-04-24
US20220280418A1 (en) 2022-09-08
JP7110495B2 (ja) 2022-08-01
ZA202202320B (en) 2024-06-26
AU2020328351B2 (en) 2026-03-05
PH12022550349A1 (en) 2022-12-12
JP7635187B2 (ja) 2025-02-25

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220614

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220922

R150 Certificate of patent or registration of utility model

Ref document number: 7148733

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250